AI assistant
CSL Ltd. — Board/Management Information 2021
Jun 24, 2021
17854_rns_2021-06-24_18ab26ab-47f4-4e1e-9968-305647315ce7.pdf
Board/Management Information
Open in viewerOpens in your device viewer
For immediate release
25 June 2021
==> picture [205 x 32] intentionally omitted <==
==> picture [58 x 30] intentionally omitted <==
==> picture [262 x 27] intentionally omitted <==
Resignation of Director
CSL Limited (ASX:CSL; USOTC:CSLLY) advises that the CSL Board of Directors has regretfully accepted the resignation of Mr Abbas Hussain as an independent NonExecutive Director, effective immediately. Mr Hussain submitted his resignation after being appointed as the Chief Executive Officer of Vifor Pharma Group, a global speciality pharmaceuticals group based in Switzerland.
Mr Hussain joined CSL as an independent Non-Executive Director in 2017 and has served on the Human Resources and Remuneration Committee, and the Innovation and Development Committee.
CSL’s Chair, Dr Brian McNamee AO said “I would like to thank Abbas for his contribution to CSL over the last four years. His global biopharmaceutical experience and deep understanding of manufacturing and product development have meant he brought deep strategic and industry insight to CSL”.
The CSL Board and management team wish to thank Abbas for his contribution to the Company and wish him every success in his new role.
Authorised by Fiona Mead Company Secretary
FURTHER INFORMATION
For further information, please contact:
Investors: Media: Stephen McKeon Jimmy Baker Associate Director Investor Relations Communications, Asia Pacific CSL Limited CSL Limited Telephone: +61 402 231 696 +61 45 090 9211 Email: [email protected] Email: [email protected]
® Trademarks of CSL Limited or its affiliates.
==> picture [99 x 7] intentionally omitted <==